In the paper they show that NK-92 cells, the most “NK-like” cell line currently available, can grow and thrive in RPMI medium supplemented with IL-2, instead of a costly and complicated specific medium used up until now. Presently a therapeutic platform in clinical trials and an important research tool, this discovery can aid scientists in reducing the cost of working with this important cell line in research, and hopefully thus making future treatments with NK-92 cells easier and more affordable.
Fig 1: Schematic representation of the growth conditions and media of the NK-92 and growth progression in the media.
